PURPOSE: To evaluate the therapeutic complications due to the use of immunosupressors in patients with nephropathy. METHODS: 76 patients who had used steroids and cyclophosphamide were retrospectively studied. The cases were divided into three groups: G1= 15 patients with Systemic Lupus Erythematosus without renal lesion; G2= 33 patients with lupus nephritis and G3= 28 patients with nephrotic syndrome owing to idiopathic glomerulopathy. RESULTS: There were no differences related to time of follow up (G1= 42.4 +/- 51, G2= 52.3 +/- 51, G3= 41.8 +/- 47.8 months), total used dosage of steroids (G1= 20, G2= 28, G3= 16 grams) and time of drug use (G1= 20, G2= 26, G3= 14.5 months). About cyclophosphamide use, there was no difference in the percent...
Background: The aim of this study was to report the outcome of pure membranous lupus nephropathy tre...
Item does not contain fulltextOBJECTIVES: The objectives of this study are to analyse the long-term ...
Background: The prognosis of SLE is influenced by the onset of glomerulonephritis. Clinical trials i...
A utilização terapêutica de doses elevadas de imunossupressores pode promover diversas complicações,...
Background: Systemic lupus erythematosus (SLE) is a chronic, auto immune disorder and multisystem. T...
Contains fulltext : 87620.pdf (publisher's version ) (Open Access)Renal involvemen...
Objectives: The treatment of lupus membranous nephritis (LMN), a lupus subset that carries a high mo...
OBJECTIVE: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that i...
Contains fulltext : 50854.pdf (publisher's version ) (Closed access)Until recently...
OBJECTIVE: Intravenous cyclophosphamide is widely used in the treatment of lupus nephritis. In order...
Introduction: Treatment of lupus nephritis consists of six months of induction immunosuppression fol...
OBJECTIVE: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that i...
p.1365-1372Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. Howeve...
Introduction: Systemic Lupus Erythematosus (SLE) is a complex disease process that involves the ins...
Introduction: Lupus is a chronic autoimmune systemic pathology; lupus nephritis is theresult of rena...
Background: The aim of this study was to report the outcome of pure membranous lupus nephropathy tre...
Item does not contain fulltextOBJECTIVES: The objectives of this study are to analyse the long-term ...
Background: The prognosis of SLE is influenced by the onset of glomerulonephritis. Clinical trials i...
A utilização terapêutica de doses elevadas de imunossupressores pode promover diversas complicações,...
Background: Systemic lupus erythematosus (SLE) is a chronic, auto immune disorder and multisystem. T...
Contains fulltext : 87620.pdf (publisher's version ) (Open Access)Renal involvemen...
Objectives: The treatment of lupus membranous nephritis (LMN), a lupus subset that carries a high mo...
OBJECTIVE: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that i...
Contains fulltext : 50854.pdf (publisher's version ) (Closed access)Until recently...
OBJECTIVE: Intravenous cyclophosphamide is widely used in the treatment of lupus nephritis. In order...
Introduction: Treatment of lupus nephritis consists of six months of induction immunosuppression fol...
OBJECTIVE: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that i...
p.1365-1372Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. Howeve...
Introduction: Systemic Lupus Erythematosus (SLE) is a complex disease process that involves the ins...
Introduction: Lupus is a chronic autoimmune systemic pathology; lupus nephritis is theresult of rena...
Background: The aim of this study was to report the outcome of pure membranous lupus nephropathy tre...
Item does not contain fulltextOBJECTIVES: The objectives of this study are to analyse the long-term ...
Background: The prognosis of SLE is influenced by the onset of glomerulonephritis. Clinical trials i...